340B Drug Pricing Program
The AHA hosted a webinar for members on Aug. 5, during which AHA staff discussed the recently released CY 2027 Physician Fee Schedule proposed rule. The proposed rule includes updates to physician fee schedule rates and other aspects of physician payment. It also contains proposals related to the…
The Centers for Medicare & Medicaid Services (CMS) is seeking comments on its hospital outpatient prospective payment system proposed rule for calendar year 2027. Comments are due to CMS by Aug. 31.
A bipartisan group of senators Aug. 5 introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act), a bill aimed at providing statutory clarity for the 340B Drug Pricing Program while establishing new…
A bipartisan group of senators today introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act),
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers to use rebates rather than upfront discounts to effectuate the 340B ceiling price for certain drugs purchased by 340B covered entities.
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers to use rebates rather than upfront discounts to effectuate the 340B ceiling price for certain drugs purchased by 340B covered entities.
The AHA is deeply concerned that HHS has chosen to move forward with a 340B Rebate Model Program despite the overwhelming evidence that it will impose massive new administrative and financial burdens on hospitals that serve America's most vulnerable patients.
The U.S. District Court for the District of Columbia July 21 upheld a lower court’s decision that Section 340B of the Public Health Service Act does not permit drug companies to impose proposed rebate models on 340B purchasers unless the Secretary of the Department of Health and Human…
The U.S. District Court for the District of Columbia today upheld a lower court’s decision that Section 340B of the Public Health Service Act does not permit drug companies to impose proposed rebate models on 340B purchasers unless the Secretary of the Department of Health and Human Services…
The Centers for Medicare & Medicaid Services (CMS) July 7 published its calendar year (CY) 2027 outpatient prospective payment system (PPS) and ambulatory surgical center (ASC) proposed rule.